128 filings
DEFR14A
NXGL
Nexgel Inc
3 May 24
Revised proxy
5:10pm
DEF 14A
NXGL
Nexgel Inc
Definitive proxy
29 Apr 24
5:25pm
10-K
2023 FY
NXGL
Nexgel Inc
Annual report
9 Apr 24
10:00pm
NT 10-K
NXGL
Nexgel Inc
2 Apr 24
Notice of late annual filing
6:05am
8-K
NXGL
Nexgel Inc
1 Apr 24
Results of Operations and Financial Condition
8:41am
424B5
yjudyrbdnjvpjoo
21 Feb 24
Prospectus supplement for primary offering
4:17pm
8-K
a8d9gprk
21 Feb 24
NEXGEL Announces $975,000 Registered Direct Offering Led by Insiders
4:15pm
8-K
6c0qrh 4j
31 Jan 24
Regulation FD Disclosure
9:05am
8-K
l66eszz6
16 Jan 24
Departure of Directors or Certain Officers
4:30pm
8-K
ruw etw9m
29 Dec 23
Entry into a Material Definitive Agreement
4:30pm
8-K
ar18q3cody3
12 Dec 23
Departure of Directors or Certain Officers
4:52pm
8-K
d5ukd6z0j9w
11 Dec 23
NEXGEL Announces Partnership with STADA to Distribute and Commercialize Consumer Health OTC Products in North America
8:15am
8-K
vbvn9ksx 8x3kzr
5 Dec 23
NEXGEL Acquires Kenkoderm Psoriasis Skincare Line
8:10am
8-K
vogc1
13 Nov 23
NEXGEL Reports Record Third Quarter 2023 Revenue of $1.2 Million, an Increase of 115% Year-Over-Year
5:10pm
8-K
seccy4ixi91tqrpblg
30 Oct 23
NEXGEL Secures Supply Agreement with AbbVie
8:30am
8-K
kbrymezx9k9w5d ig
14 Aug 23
NEXGEL Reports Second Quarter 2023 Record Revenue of $1.17 Million, an Increase of 108% Year-Over-Year
5:29pm
8-K
f8ir51y9
9 Jun 23
Submission of Matters to a Vote of Security Holders
5:01pm
EFFECT
786qr5olzl8axqq5cl5n
8 Jun 23
Notice of effectiveness
12:15am